Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy

Inclusion Criteria

• •Histologically or cytologically confirmed diagnosis of early stage prostate cancer.
• •Must be considered either low-risk (T1-T2a, Gleason ≤ 6, PSA \< 10 ng/mL) or favorable intermediate-risk (Gleason 3 +4 = 7, percentage of positive biopsy cores \< 50%, no more than one NCCN intermediate risk factor).
• •Prior androgen deprivation therapy is allowed and may have been initiated up to 6 months prior to the date of the HDR implant. The complete duration of androgen deprivation therapy can range from 4 months to 36 months provided it has been initiated no more than 6 months prior to the date of the HDR implant.
• •At least 18 years of age.
• •ECOG performance status ≤ 2
• •Able to understand and willing to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).